Post-surgical chemotherapy versus surgery alone for resectable gastric cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Diaz Nieto, Rafael ^a   Orti Rodríguez, Rafael ^a   Winslet, Marc ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OUTCOME; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETURN TO WORK; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; GASTRECTOMY; LYMPH NODE DISSECTION; METHODOLOGY; MORTALITY; STOMACH TUMOR; PROCEDURES; STOMACH NEOPLASMS;

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FLUOROURACIL; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84898719960     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008415.pub2     Document Type: Review

References (103)

1. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet March, 1989;1(8638):571-4.
2. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, et al.Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Annals of Oncology 2002;13:299-307.
3. Bonfanti G. Adjuvant treatments following curative resection for gastric cancer. The Italian Gastrointestinal Tumor Study Group. British Journal of Surgery 1988;75(11):1100-4.
4. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, et al.Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Annals of Oncology 2005;16(9):1488-97.
5. Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, et al.Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. American Journal of Surgery 2004;187(3):440-5.
6. Chou FF, Sheen-Chen SM, Liu PP, Chen FC. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. Journal of Surgical Oncology 1994;57(4):239-42.
7. Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, et al.Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. Journal of Clinical Oncology 1999;17(12):3810-5.
8. Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, et al.A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. Journal of Clinical Oncology 1990;8(8):1362-9.
9. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, et al.Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase IIItrial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Annals of Oncology 2007;18(8):1354-8.
10. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al.Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. Journal of National Cancer Institute 2008;100(6):388-98.
11. Douglas OH. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1982;49(6):1116-22.
12. Engstrom PF, Lawn PT, Douglas HO, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cancer 1985;55(9):1868-73.
13. Fielding JW, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A, et al.An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World Journal of Surgery 1983;7(3):390-9.
14. Fujimoto S, Akao T, Itoh B, Koshizuka I, Koyano K. Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. Annals of Surgery 1977;185(4):462-6.
15. Grau JJ, Estapé J, Alcobendas F, Pera C, Daniels M, Terés J. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. European Journal of Cancer 1993;29(3):340-2.
16. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994;343(8909):1309-12.
17. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1983;52:1105-12.
18. Huguier M, Destroyes JP, Baschet C, Le Henand F, Bernard PF. Gastric carcinoma treated by chemotherapy after resection: a controlled study. American Journal of Surgery 1980;139(2):197-9.
19. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Annals of Surgery 1992;216(3):269-78.
20. Krook JE, O'Connell MJ, Wieand HS, Beart RW Jr, Leigh JE, Kugler JW, et al.A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991;67(10):2454-8.
21. Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T, et al.Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology 2010;78(1):54-61.
22. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, et al.Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. Journal of Clinical Oncology 1995;13(11):2757-63.
23. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, et al.Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Annals of Surgical Oncology 1995;2(6):488-94.
24. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al.Adjuvant mitomycin and fluorouracil followed by oral uracil plustegafur in serosa-negative gastric cancer: a randomised trial. Lancet 1999;354(9175):273-7.
25. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al.Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. British Journal of Surgery 2007;94(12):1468-76.
26. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al.Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. Journal of Clinical Oncology 2003;21(12):2282-7.
27. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, et al.Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. British Journal of Cancer 2001;84(7):878-80.
28. Nitti D, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, et al.Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Annals of Oncology 2006;17(2):262-9.
29. Nitti J, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, et al.Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD. Annals of Oncology 2006;17:262-9.
30. Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3-to 6-year follow up of a randomized clinical trial. Cancer Immunology, Immunotherapy 1983;14(3):167-71.
31. Popiela T, Zembala M, Oszacki J, Jedrychowski W. A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer. Cancer Immunology, Immunotherapy 1982;13(3):182-4.
32. Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 2004;7:240-5.
33. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al.Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New England Journal of Medicine 2007;357(18):1810-20.
34. Tentes AA, Markakidis SK, Karanikiotis C, Fiska A, Tentes IK, Manolopoulos VG, et al.Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Langenbeck's Archives of Surgery 2006;391(2):124-9.
35. Alcobendas F, Milla A, Estape J. Mitomycin C as an adjuvant in resected gastric cancer. Annals of Surgery 1983;198(1):13-7.
36. Bresciani C, Gama-Rodrigues J, Strassmann V, Waitzberg DL, Matsuda M, Pinotti HW. Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study. "Revista do Hospital Das Clinicas; Faculdade de Medicina da Universidade de Sao Paulo" 2000;55(4):129-36.
37. Chen YP, Yang JS, Liu DT, Yang WP. Long-term effects of proglumide on resection of cardiac adenocarcinoma. World Journal of Gastroenterology 2005;11(17):2549-51.
38. Chen S, Chen YB, Zhou ZW, Li W, Sun XW, Xu DZ, et al Li. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer. American Journal of Clinical Oncology 2011;34(3):309-13.
39. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2006;355(1):11-20.
40. Estape J, Grau JJ, Lcobendas F, Curto J, Daniels M, Viñolas N, et al.Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Annals of Surgery 1991;213(3):219-21.
41. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al.Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine 2001;345(10):725-30.
42. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. Journal of Clinical Oncology 1984;2(11):1249-54.
43. Nio Y. A comprehensive multi institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric-cancer surgery. Annals of Surgery 1992;216(1):44-54.
44. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al.Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated normogram. Annals of Surgery 2010;251(4):640-6.
45. Yamamura Y, Yasue M, Kito T, Nakazato H, Yamada E. Adjuvant immunochemotherapy combined with OK-432 following surgery of stomach cancer. Gan To Kagaku Ryoho [Cancer and Chemotherapy] 1986;10(7):1603-9.
46. Yu CC, Levison DA, Dunn JA, Ward LC, Demonakou M, Allum WH, et al.Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. British Journal of Cancer 1995;71(5):1106-10.
47. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379(9813):315-21.
48. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al.Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology 2011;29(33):4387-93.
49. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010;116(11):2511-8.
50. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Annals of Oncology 2003;14 Suppl 2:ii31-6. [PUBMED: 12810455]
51. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal verus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Annals of Surgery 1999;230(2):170-8.
52. Crew KD, Neugut AI. Epidemiology of gastric cancer. World Journal of Gastroenterology 2006;12(3):354-62. [PUBMED: 16489633]
53. Cancer Research UK. Stomach cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/stomach-cancer-world/ (accessed 03 December 2012).
54. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al.Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative group. British Journal of Cancer 1999;79(9-10):1522-30.
55. Davies J, Johnston D, Sue-Ling H, Young S, May J, Griffith J, et al.Total or subtotal gastrectomy for gastric adenocarcinoma? A study of quality of life. World Journal of Surgery 1998;22(10):1048-55.
56. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et al.Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. European Journal of Surgical Oncology 2004;30(3):303-8.
57. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
58. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
59. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al.Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. Journal of the National Cancer Institute 2008;100(6):388-98.
60. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. European Journal of Cancer 1999;35(7):1059-64. [PUBMED: 10533448]
61. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, et al.Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371(9606):29-40. [PUBMED: 18177773]
62. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
63. Eguchi T, Kodera Y, Nakanishi H, Yokoyama H, Ohashi N, Ito Y, et al.The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo 2008;22(6):707-12. [PUBMED: 19180995]
64. Food, Drugs Administration. US Food and Drug Administration home page. www.fda.gov (accessed 17 January 2012).
65. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. [CENTRAL: CD004421; DOI: 10.1002/14651858.CD004421.pub2]
66. Forman D, Delaney B, Kuipers E, Malthaner R, Moayyedi P, Gardener E, et al.Cochrane Upper Gastrointestinal and Pancreatic Diseases Group. In: The Cochrane Library, Issue 2, 2010. Chichester: Wiley-Blackwell. Updated quarterly.
67. International Agency for Research on Cancer (WHO). Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. http://globocan.iarc.fr/ (accessed 03 December 2012).
68. Gouzi JL, Huguier M, Faqniez PL, Launois B, Flamant Y, Lacaine F, et al.Total gastrectomy versus partial gastrectomy of adenocarcinoma of the antrum. A French prospective controlled study. Annales de Chirugie 1989;43(5):356-60.
69. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery 2009;96(4):342-9.
70. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al.Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. Journal of Clinical Oncology 2004;22(11):2069-77.
71. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. Journal of Clinical Oncology 1993;11(8):1441-7.
72. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
73. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
74. Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, Chen JP, et al.Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World Journal of Gastroenterology 2002;8(6):1023-8. [PUBMED: 12439918]
75. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA: A Cancer Journal for Clinicians 2010;60(5):277-300.
76. Jeung HC, Rha SY, Shin SJ, Ahn JB, Roh JK, Park CH, et al.Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemotherapy and Pharmacology 2009;63(5):919-27. [PUBMED: 18712389]
77. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Annals of Surgery 1992;216(3):269-78; discussion 278-9. [PUBMED: 1417176]
78. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
79. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
80. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al.Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. Annals of Oncology 2000;11(7):837-43. [PUBMED: 10997811]
81. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. Journal of the National Cancer Institute 2008;100(24):1780-91. [PUBMED: 19066278]
82. McCulloch P, Nita ME, Kazi H, Gama-Rodriques J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001964.pub2]
83. Memon MA, Subramanya MS, Khan S, Hossain MB, Osland E, Memon B. Meta-Analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Annals of Surgery 2011;253(5):900-11.
84. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
85. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5(1):1-5.
86. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
87. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. Journal of Chemotherapy 2006;18(3):311-7. [PUBMED: 17129844]
88. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A, ESMO Guidelines Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010;21(5):50-4.
89. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al.Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303(17):1729-37.
90. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [PUBMED: 9921604]
91. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
92. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
93. Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. Journal of Surgical Oncology 2010;101:687-92.
94. Slanger TE, Schwarzbach M, Hofheinz R, Kienle P, Jensen K, Kieser M, et al.Perioperative chemotherapy versus primary surgery for locoregionally advanced resectable adenocarcinoma of the stomach, gastroesophageal junction and lower esophagus. Cochrane Database of Systematic Reviews 2009, Issue 4. [CENTRAL: CD008107; DOI: 10.1002/14651858.CD008107.pub2]
95. Songun I, Putter H, Kranenbarg EM, Sasako M, Van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology 2010;11(5):439-49.
96. Stats Direct Ltd. StatsDirect statistical software. 2.7. England: StatsDirect Ltd, 2008.
97. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. British Journal of Surgery 2009;96(1):26-33.
98. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [PUBMED: 17555582]
99. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, et al.Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004064.pub2]
100. World Health Organization. Handbook for reporting results of cancer treatment. Vol. WHO Offset Publication No. 48, Geneva: World Health Organization, 1979. [http://whqlibdoc.who.int/publications/9241700483.pdf]
101. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
102. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al.Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncology 2006;7(4):309-15.
103. Wu B, Ye M, Chen H, Shen JF. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics 2012;34(2):468-79.